Iovance Biotherapeutics

Iovance Biotherapeutics

Yahoo Finance • 7 days ago

This Stock Is Up 74% This Year: Is It Too Late to Buy?

Key Points Iovance Biotherapeutics is making strong regulatory and commercial progress with its key product. However, it faces several risks that could send the stock plummeting. 10 stocks we like better than Iovance Biotherapeutics › Af... Full story

Yahoo Finance • 11 days ago

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare is changing through AI and personalized cell therapy. Which of these high-growth innovators represents the better risk-adjusted opportunity for your portfolio today as you evaluate Heartflow Inc. (NASDAQ:HTFL) and Iovance Biothe... Full story

Yahoo Finance • 22 days ago

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key Points Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers. Should inve... Full story

Yahoo Finance • 26 days ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltratin... Full story

Yahoo Finance • last month

Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is among the hidden penny stocks to invest in. As of June 10, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was trading near the low levels reported on June 3, before the stock appreciated followin... Full story

Yahoo Finance • last month

Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the top penny stocks to buy in investors’ stock portfolio. On June 1, research firm Citizens reiterated a Market Outperform rating on Iovanace Biotherapeutics (NASDAQ:IOVA) with a $5 pr... Full story

Yahoo Finance • last month

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc... Full story

Yahoo Finance • last month

FDA Clears IND For Iovance's IOV-5001 In Treating Cancer; Phase 1/2 Enrollment Planned For H2 2026

(RTTNews) - Iovance Biotherapeutics Inc. (IOVA), a commercial-stage biopharmaceutical company, on Monday announced FDA clearance of the investigational new drug (IND) submission for IOV-5001, a tumor-infiltrating lymphocyte (TIL) therapy.... Full story

Yahoo Finance • last month

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focus... Full story

Yahoo Finance • 2 months ago

Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies f... Full story

Yahoo Finance • 3 months ago

Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?

Is VKTX a good stock to buy? We came across a bullish thesis on Viking Therapeutics, Inc. on Charlie Evans’s Substack by Charlie Evans PhD. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.'s share was... Full story

Yahoo Finance • 3 months ago

Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug

Iovance Biotherapeutics Inc (NASDAQ:IOVA) is among the must-buy penny stocks to invest in now. The stock has climbed more than 66% over the past six months and currently trades at around $3.86. On April 10, Jefferies reaffirmed a Buy ratin... Full story

Yahoo Finance • 3 months ago

Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster

Neurocrine Biosciences logo 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Neurocrine Biosciences (NASDAQ:NBIX) detailed its planned acquisition of Soleno Therapeutics on a conference call Monday, outlining the deal terms, the s... Full story

Yahoo Finance • 4 months ago

Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine

Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track the development of AI-driven precision medicine and suppo... Full story

Yahoo Finance • 4 months ago

UBS Raises PT on Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Low Risk Penny Stocks to Buy Now. On March 5, UBS analyst David Dai raised the firm’s price target on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) from $2 to $4, while maintaining a... Full story

Yahoo Finance • 5 months ago

Iovance Biotherapeutics GAAP EPS of -$0.18 in-line, revenue of $86.71M beats by $5.7M

* Iovance Biotherapeutics press release [https://seekingalpha.com/pr/20410351-iovance-biotherapeutics-highlights-strong-fourth-quarter-and-full-year-2025-results-business] (IOVA [https://seekingalpha.com/symbol/IOVA]): Q4 GAAP EPS of -$0... Full story

Yahoo Finance • 5 months ago

Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds?

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best immunotherapy stocks to buy according to hedge funds. On February 5, Goldman Sachs lifted the price target on Iovance Biotherapeutics Inc. (NASDAQ:IOVA) to $2 from $1.50 while m... Full story

Yahoo Finance • 5 months ago

Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best stocks under $3 to invest in. On January 9, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) announced that it expects to achieve its previously disclosed full-year 2025 revenue guida... Full story

Yahoo Finance • 5 months ago

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL)... Full story

Yahoo Finance • 6 months ago

Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best biotech penny stocks to buy according to analysts. On December 17, Barclays analyst Etzer Darout raised the firm’s price target on Iovance Biotherapeutics to $10 from $9, while... Full story